spacer
home > pmps > winter 2019 > a comparative study of directly compressible orally disintegrating tablet platforms
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Comparative Study of Directly Compressible Orally Disintegrating Tablet Platforms

The world’s population is widely acknowledged to be ageing, resulting in the demand for geriatric medicines increasing, and this trend will continue. Plenty of evidence shows that children are not just small-sized human beings, a child’s metabolism is significantly different to that of an adult, and ageappropriate formulations have to be developed. In fact, since 2007, it has been compulsory for a paediatric investigational plan to be submitted to the Paediatrics Committee at the EMA at the end of the first phase of testing a new drug in adults (1). Thus, a need to develop formulations targeting these two population groups is clear. Since children and elderly people are not easily persuaded to take medicines, compliance is a significant challenge. Orally disintegrating tablets (ODTs) can overcome this because, since they are usually smaller, they disintegrate rapidly in the mouth and they have a pleasant mouthfeel and flavour, making them, overall, easier to take.

ODTs: A Challenging Oral Dosage Form

The combined ODT markets in the US, the EU, and Japan doubled in size over the past four years. According to reports, the global ODT market is predicted to grow at a significant pace: revenue growth is anticipated to rise from an estimated US $11.4 billion in 2017 to about US $27 billion by the end of 2025 (2). As a result, more than 450 over-thecounter and prescription ODT products are now available on the market. ODTs can be produced by different technologies, including direct compression (DC), lyophilisation (freeze drying), moulding, mass extrusion, and spray-drying (3). All these technologies have their own disadvantages, such as relatively slow disintegration, poor mouthfeel or taste masking, cost-ineffective manufacturing, a requirement for special packaging due to hygroscopicity, or low chemical and/ or mechanical stability. However, DC platforms have clear advantages in terms of cost-effectiveness and ease of ODT manufacturing compared to other technologies. Figure 1 shows the key performance attributes expected in a DC ODT platform. In addition to fast disintegration, an ODT platform must also be stable, have a good level of inertness, good flowability and compactability, and must contribute to the pleasant mouthfeel of the final formulation.



Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Carolina Diaz Quijano is Head of Technical Services for consumer goods at Omya, joining the company in 2013. Prior to her current position, Carolina has worked as Senior Scientist for Mineral Surface Chemistry and as Manager for Technical Services and Innovation. She has also previously worked as a research collaborator in protein engineering at the University of Zurich, Switzerland, and in diagnostics and genetic profiles at the start-up Stab Vida in Portugal. She earned a PhD in life sciences from ETH Zurich, Switzerland.
spacer
Dr Carolina Diaz Quijano
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement